ArticleKidney medicine2023

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.

Obbo W Bredewold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.